In Vitro Interaction of Caspofungin Acetate with Voriconazole against Clinical Isolates of Aspergillus spp
Open Access
- 1 September 2002
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (9) , 3039-3041
- https://doi.org/10.1128/aac.46.9.3039-3041.2002
Abstract
The interaction between caspofungin acetate and voriconazole was studied in vitro by using 48 clinical Aspergillus spp. isolates obtained from patients with invasive aspergillosis. MICs were determined by the NCCLS broth microdilution method. Synergy, defined as a fractional inhibitory concentration (FIC) index of <1, was detected in 87.5% of the interactions; an additive effect, defined as an FIC index of 1.0, was observed in 4.2% of the interactions; and a subadditive effect, defined as an FIC index of 1.0 to 2.0, was found in 8.3% of the interactions. No antagonism was observed. Animal models are required to validate the in vivo significance of these in vitro data presented for the combination of caspofungin and voriconazole.Keywords
This publication has 17 references indexed in Scilit:
- In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium sppAntimicrobial Agents and Chemotherapy, 2002
- Optimal Susceptibility Testing Conditions for Detection of Azole Resistance in Aspergillus spp.: NCCLS Collaborative EvaluationAntimicrobial Agents and Chemotherapy, 2001
- Synergism of Voriconazole and Terbinafine against Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal CandidiasisAntimicrobial Agents and Chemotherapy, 2001
- Synergistic interaction of terbinafine with triazoles or amphotericin B againstAspergillusspeciesMedical Mycology, 2001
- In Vitro Susceptibility Testing Methods for Caspofungin against Aspergillus and Fusarium IsolatesAntimicrobial Agents and Chemotherapy, 2001
- Aspergillosis UpdateMedicine, 2000
- Invasive Aspergillosis Disease Spectrum, Treatment Practices, and OutcomesMedicine, 2000
- Current and Emerging Azole Antifungal AgentsClinical Microbiology Reviews, 1999
- In Vitro Activity of Two Echinocandin Derivatives, LY303366 and MK-0991 (L-743,792), Against Clinical Isolates of Aspergillus, Fusarium, Rhizopus, and Other Filamentous FungiDiagnostic Microbiology and Infectious Disease, 1998
- Invasive AspergillosisClinical Infectious Diseases, 1998